The second candidate, PAR5/PWAR5 (Prader Willi/Angelman region RNA 5), has also been associated with other carcinomas, and acts by reducing EZH2 activity, although its potential role in HCC awaits validation. The gene discussed is PWAR5; the disease is hepatocellular carcinoma.